Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 3/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970535 | 0.93 | ALDH1A1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19970497 | 0.93 | ALDH1A1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20111183 | 0.88 | TLR4 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19970505 | 0.87 | P2RX7 (0.31) | P2RX7 | |
| SCHEMBL19970519 | 0.86 | LMNA (0.36) | ALDH1A1GAACYP2C19 | |
| SCHEMBL19970533 | 0.86 | LMNA (0.36) | ALDH1A1GAACYP2C19 | |
| SCHEMBL19970525 | 0.86 | LMNA (0.36) | ALDH1A1GAACYP2C19 | |
| SCHEMBL19970489 | 0.86 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19970476 | 0.83 | GRM2 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL19970499 | 0.82 | KMT2A (0.37) | ALDH1A1GAAP2RX7CYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-3296296-A1 | CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | PSEN1 4196/4885PSEN2 4444/4885APH1B 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.